Seminars in Hematology
Volume 44 , Pages S1-S3 , April 2007

Atypical Chronic Myeloproliferative Disorders: Genes and Imatinib-Sensitive Targets

  • Giovanni Martinelli

      Affiliations

    • Corresponding Author InformationAddress correspondence to Giovanni Martinelli, MD, Institute of Hematology and Medical Oncology, “L. & A. Seràgnoli,” Via Massarenti, 9, 40138 Bologna, Italy.

References 

  1. Baselga J. Targeting tyrosine kinases in cancer: The second wave. Science. 2006;312:1175–1178
  2. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–187
  3. Friedrich MJ. From bedside to bench: Treatment for rare blood disorder yields clues to disease mechanism. J Natl Cancer Inst. 2003;95:1102–1103
  4. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100–104
  5. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001;97:2440–2448
  6. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139–145
  7. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925–932
  8. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005;105:3127–3132
  9. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–1432
  10. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004
  11. Druker BJ, Guilhot F, O’Brien S, Gathmann I, Kantarjian H, Gattermann N, et al. IRIS Investigators Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417
  12. Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol. 2001;193:505–510
  13. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710
  14. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480
  15. Blanke C, Joensuu H, Demetri G, Heinrich M, Eisenberg B, Fletcher C, et al. Outcome of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate: four-year follow-up of a phase II randomized trial. 2006;Presented at the American Society for Clinical Oncology. Gastrointestinal Cancers Symposium, San Francisco, CA, January 28-30, (abstr 7)
  16. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577–1578
  17. Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101:3391–3397
  18. Schaller JL, Burkland GA. Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed. 2001;3:9
  19. Salem Z, Zalloua PA, Chehal A, Bitar N, Abboud M, Kadri A, et al. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Hematol J. 2003;4:410–412
  20. Cools J. FIP1L1-PDGFRA-negative hypereosinophilic syndrome: Not the usual suspects. Haematologica. 2005;90:577B
  21. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102:3093–3096
  22. Martinelli G, Cilloni D, Rondoni M, Messa F, Ottaviani E, Gottardi E, et al. Imatinib mesylate can induce molecular complete remission in idiopathic hypereosinophilic syndrome (HES) (A phase II multicentric Italian clinical trial). Blood. 2005;106:113a;(abstr 375)
  23. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, et al. FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006;30:965–970
  24. Roche-Lestienne C, Lepers S, Soenen-Cornu V, Kahn JE, Lai JL, Hachulla E, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia. 2005;19:792–798
  25. Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia. 2006;20:827–832
  26. Bowen DT. Chronic myelomonocytic leukemia: Lost in classification?. Hematol Oncol. 2005;23:26–33
  27. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML—Dysplastic versus proliferative type. Leuk Res. 1998;22:871–878
  28. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481–487
  29. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor beta. Acta Haematol. 2002;107:113–122
  30. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307–316
  31. Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor β receptor (PDGFβR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood. 1998;91:4419–4426
  32. Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood. 2002;100:1088–1091
  33. Levine RL, Wadleigh M, Sternberg DW, Wlodarska I, Galinsky I, Stone RM, et al. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia. 2005;19:27–30
  34. Morerio C, Acquila M, Rosanda C, Rapella A, Dufour C, Locatelli F, et al. HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res. 2004;64:2649–2651
  35. Kurzrock R, Bueso-Ramos CE, Kantarjian H, Freireich E, Tucker SL, Siciliano M, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol. 2001;19:2915–2926
  36. Barbouti A, Ahlgren T, Johansson B, Hoglund M, Lassen C, Turesson I, et al. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. Br J Haematol. 2003;122:85–93
  37. Kulkarni S, Heath C, Parker S, Chase A, Iqbal S, Pocock CF, et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor β in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res. 2000;60:3592–3598
  38. Safley AM, Sebastian S, Collins TS, Tirado CA, Stenzel TT, Gong JZ, et al. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. Genes Chromosomes Cancer. 2004;40:44–50
  39. Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, Senent L, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet. 2002;11:1391–1397
  40. Vizmanos JL, Novo FJ, Roman JP, Baxter EJ, Lahortiga I, Larrayoz MJ, et al. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res. 2004;64:2673–2676
  41. Grand FH, Burgstaller S, Kuhr T, Baxter EJ, Webersinke G, Thaler J, et al. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor β in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res. 2004;64:7216–7219
  42. Garcia JL, Font de Mora J, Hernandez JM, Queizan JA, Gutierrez NC, San Miguel JF. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. Blood. 2003;102:2699–2700(letter)
  43. Bastie JN, Garcia I, Terre C, Cross NC, Mahon FX, Castaigne S. Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor β-gene. Haematologica. 2004;89:1263–1264(letter)

PII: S0037-1963(07)00024-8

doi: 10.1053/j.seminhematol.2007.02.003

Seminars in Hematology
Volume 44 , Pages S1-S3 , April 2007

Article Tools